ID   ALL-PO
AC   CVCL_1069
SY   ALLPO; AllPO
DR   CLO; CLO_0001705
DR   CLDB; cl5399
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_1069
DR   Cell_Model_Passport; SIDM00211
DR   ChEMBL-Cells; CHEMBL3308227
DR   ChEMBL-Targets; CHEMBL2366294
DR   Cosmic; 910944
DR   Cosmic-CLP; 910944
DR   DepMap; ACH-002209
DR   EGA; EGAS00001000978
DR   GDSC; 910944
DR   GEO; GSM1669596
DR   GEO; GSM5137706
DR   GEO; GSM5137750
DR   IARC_TP53; 21173
DR   ICLC; HTL01003
DR   LINCS_LDP; LCL-1043
DR   PharmacoDB; ALLPO_58_2019
DR   PRIDE; PXD023662
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1069
DR   Wikidata; Q54749226
RX   PubMed=9444945;
RX   PubMed=14671638;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35354797;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (PubMed=14671638; PubMed=35354797).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.07%; East Asian, North=2.2%; East Asian, South=1.8%; South Asian=1.45%; European, North=52.99%; European, South=41.49% (PubMed=30894373).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): Cosmic-CLP; ICLC
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 11,12
ST   D16S539: 13
ST   D21S11: 29,30
ST   D5S818: 11,12
ST   D7S820: 9,11
ST   TH01: 6,7
ST   TPOX: 8,9
ST   vWA: 16,17
DI   NCIt; C9140; Childhood B acute lymphoblastic leukemia
DI   NCIt; C80342; B acute lymphoblastic leukemia with t(v;11q23.3) MLL rearranged
DI   ORDO; Orphanet_585918; B-lymphoblastic leukemia/lymphoma with t(v;11q23.3)
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   4M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 37
//
RX   PubMed=9444945; DOI=10.1016/S0145-2126(97)00092-1;
RA   Gobbi A., Di Berardino C., Scanziani E., Garofalo A., Rivolta A.,
RA   Fontana G., Rambaldi A., Giavazzi R., Biondi A.;
RT   "A human acute lymphoblastic leukemia line with the T(4;11)
RT   translocation as a model of minimal residual disease in SCID mice.";
RL   Leuk. Res. 21:1107-1114(1997).
//
RX   PubMed=14671638; DOI=10.1038/sj.leu.2403236;
RA   Drexler H.G., Quentmeier H., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   MLL gene alterations.";
RL   Leukemia 18:227-232(2004).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35354797; DOI=10.1038/s41467-022-29224-5;
RA   Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T.,
RA   Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E.,
RA   Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I.,
RA   Lehtio J., Vesterlund M., Jafari R.;
RT   "Integrative multi-omics and drug response profiling of childhood
RT   acute lymphoblastic leukemia cell lines.";
RL   Nat. Commun. 13:1691.1-1691.19(2022).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//